Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.35 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19682786 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP2A6ALDH1A1HIF1ACYP1B1 | |
| SCHEMBL26728094 | 0.80 | CYP1A2 (0.48) | CYP1A2CYP2A6ALDH1A1HIF1ACYP2C9 | |
| SCHEMBL2173494 | 0.79 | UGT2B7 (0.44) | CYP1A2CYP2A6ALDH1A1HIF1ACYP1B1 | |
| SCHEMBL6366989 | 0.79 | CYP1A2 (0.57) | CYP1A2CYP2A6ALDH1A1HIF1ACYP1B1 | |
| SCHEMBL25059970 | 0.78 | TRPM4 (0.46) | CYP1A2CYP2A6ALDH1A1HIF1ACYP1B1 | |
| SCHEMBL19067389 | 0.78 | NQO2 (0.55) | CYP1A2ALDH1A1HIF1ACYP2C19GABRA1 | |
| SCHEMBL5252919 | 0.78 | CYP1A2 (0.40) | CYP1A2CYP2A6ALDH1A1HIF1ACYP1B1 | |
| SCHEMBL21758895 | 0.78 | GABRA1 (0.47) | CYP1A2CYP2A6ALDH1A1HIF1ACYP1B1 | |
| SCHEMBL21302107 | 0.78 | ALDH1A1 (0.45) | CYP1A2CYP2A6ALDH1A1HIF1ACYP1B1 | |
| SCHEMBL7835784 | 0.78 | ALDH1A1 (0.37) | CYP1A2CYP2A6ALDH1A1HIF1ACYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2022135470-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2021219072-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374036-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | CYP1A2 4742/4885CYP2A6 3882/4885ALDH1A1 4243/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CYP1A2 3408/4885CYP2A6 3163/4885ALDH1A1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.